INCB081776 + retifanlimab

INCB081776 + retifanlimab is a combination therapy currently in phase 1 clinical trials for advanced solid tumors. INCB081776 is a potent and selective dual inhibitor of the receptor tyrosine kinases **AXL** and **MERTK**, which play roles in tumor cell survival, proliferation, and immune evasion. It shifts the tumor immune microenvironment from immunosuppressive to pro-inflammatory, reversing macrophage-mediated T-cell suppression and directly inhibiting tumor cell survival signaling[2][5]. Retifanlimab (INCMGA00012, branded as Zynyz) is a humanized monoclonal antibody targeting **programmed death 1 (PD-1)**, acting as a checkpoint inhibitor to restore T-cell mediated anti-tumor immunity[1][2]. The combination is designed to enhance anti-tumor efficacy through complementary immunomodulatory mechanisms: AXL/MERTK inhibition to promote immune activation and PD-1 blockade to unleash T-cell activity. Developed for advanced and metastatic malignancies, including melanoma, non-small cell lung cancer, soft-tissue sarcoma, squamous cell carcinoma of the head and neck, triple negative breast cancer, urothelial carcinoma, and other solid tumors[1].

Other names

INCB081776 + INCMGA00012retifanlimab-dlwr